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combined with precision radiotherapy and chemotherapy in 
our orthotopic GBM model is currently being evaluated.  
Conclusions: The results of this will be presented. 
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Purpose/Objective: To evaluate the impact of two TBI 
schedules on the risk of relapse and transplant-related 
mortality (TRM) in 61 patients with acute leukemia who 
received HLA matched T-cell depleted allogeneic 
hematopoietic stem cell transplantation (matched HSCT). 
Materials and Methods: 29 males and 32 females (median 
age 48 years; range 20-66) were enrolled from January 1999 
to October 2013. 41 (67.2 %) patients had acute myeloid 
leukemia (AML) and 20 (32.8%) acute lymphoid leukemia 
(ALL). 43 patients were in first complete remission (CR1), 8 
in CR2 and 10 had persistent disease. Patients in CR1 and CR2 
were analyzed as one group. Group 1 (31 patients) 
conditioning was a hyperfractionated schedule (HTBI) (1.2 Gy 
3 times a day for 4 days up to 14.4 Gy; lung dose 9 Gy) from 
day -10 to day -7. Group 2 (30 patients) conditioning was a 
single TBI (STBI) schedule (8 Gy, at a median dose-rate of 
10.7 cGy/min, lung dose 4 Gy) delivered on day -9. All 
patients received Thiotepa (10 mg/kg) and Fludarabine (160 
mg/m2 ) consecutively from day -6 to day -3 after HTBI and 
from day -8 to day -2 after STBI. Anti-thymocyte globulin 
(ATG) was administered to 27 patients to strengthen the 
immunosuppressive effect of the conditioning regimen. No 
immunosuppressive drug was administered post-transplant as 
prophylaxis for Graft versus Host Disease (GvHD). All patients 
received anti-bacterial, antifungal, antiviral, anti-
Pneumocystis prophylaxis.  
Results: Median follow-up was 63.53 months (range 2.53-
186.77). No patient rejected the transplant. Acute GvHD 
occurred in 11/61 patients (18%; 8 Grade I-II and 3 Grade III). 
Four were in the HTBI group and 7 in the STBI group; no cases 
of chronic GvHD were observed. Relapse developed in 18 
patients (29.5%). The 5-year probability of relapse was 28% 
(CI 95% 0.17-0.41). Univariate analysis showed disease 
impacted significantly on the cumulative incidence of relapse 
with AML relapsing less than ALL (p=0.035). Overall, HTBI 
tended to be better than STBI (p=0.11). Age, disease stage, 
ATG administration, GvHD did not impact upon the risk of 
relapse. The Fine and Gray model with disease and TBI as 
main factors confirmed the results of the univariate analysis. 
With a different parametrization an even lower risk of 
relapse in AML patients who received HTBI not STBI (p=0.015) 
was found. TRM occurred in 10 patients (16,39%, 4/31 after 
HTBI; 6/30 after STBI). Causes of death were infection in 8 
patients and GvHD in 2 patients. The 5-year probability of 
TRM was 18%. Univariate analysis showed age, disease and 
disease stage, ATG administration, TBI schedule, GvHD had 
no impact on TRM.  
Conclusions: In AML patients HTBI in the conditioning 
regimen for HLA matched T-depleted HSCT is more 
efficacious than STBI in reducing the risk of relapse. 
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Purpose/Objective: Even if brain cancer is a rare disease, its 
rising trend of the last three decades with its poor survival 
rate needs further analysis, possibly based on large 
randomized trials conducted on population-based data. 
Moreover, because of few available standard therapeutic 
strategies the identification of prognostic and predictive 
factors is a recent field of interest towards personalized 
treatments. The effort should be the storage of a large 
database coming from several datasets avoiding semantic 
difference and in concepts description through the adoption 
of a uniform language. Therefore our aim is to build a brain 
cancer ontology to standardize data, creating a consistent 
and specific large database in order to produce predictive 
models, useful to implement a Decision Support System 
(DSS).  
Materials and Methods: A multi-professional team, involving 
medical doctors, a mathematician and an engineer, was 
employed to design an ontology in which concepts and data 
related to brain cancer are standardized and organized in 
order to create a storage of knowledge and data. Three 
different levels of analysis were considered to classify the all 
concepts. Some of them are related to general information in 
common with other cancer types, others are brain cancer 
related. In a next step, 'atomic' data type (i.e. integer, real, 
datatime) or structured data type (i.e.: a DICOM file, an XML 
structure, etc...) were added in order to provide a range for 
the predicates. 
Results: More than 200 clinical, bio-molecular, 
neuropsychological and imaging features related to brain 
cancer were selected and classified according to three 
different levels. The first, the Registry level, includes general 
and epidemiological information as patient code, sex, age, 
gender, ethnicity, site and histology of the tumor, 
institution, the death and its cause. This level can probably 
be shared with ontologies related to other cancer sites. The 
second, the Procedure level, reports variables related to the 
muti-discipinary management of patients and brain cancer 
specific. It includes information about clinical presentation of 
the tumor, about surgery, radiotherapy or chemotherapy 
treatment, about outcomes evaluation and toxicity. We 
represented toxicities according to CTCAEv4 and RTOG scales 
and we provided also a description of therapeutic 
relationship between the two standards. The third is the 
Research level considering the elements useful for advanced 
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research project as clinical data, imaging features and 
quality of life evaluation.  
Conclusions: The creation of a formal ontology is the starting 
point to share and collect data from multiple datasets. It 
allows to obtain a clear and a common interpretation of 
concepts, to report information in standardized large 
database. Along these lines the multi-professional team has 
in use a suitable support to implement decision support 
system based on predictive models.  
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Purpose/Objective: To determine patterns of failure (POF) 
and survival outcomes in newly-diagnosed glioblastoma (ND-
GBM) patients treated on prospective phase I and II clinical 
trials using standard chemoradiotherapy in combination with 
novel chemotherapy. 
Materials and Methods: POF of 77 patients with ND-GBM 
enrolled in prospective clinical trials were reviewed. Patients 
received the current standard of care, including surgical 
debulking, conformal radiation therapy (RT), and 
temozolomide, as well as an investigational chemotherapy 
agent (everolimus, erlotinib, or vorinostat). Patients received 
follow-up MR imaging per protocol at 2-month intervals 
following treatment to evaluate response. Contrast 
enhancement (CE) from T1-weighted post-contrast MRI scans 
was used to define each recurrence volume at the time of 
progression (RecVolp). Additionally, the first suspicious scan 
containing new or increased CE was used to define the initial 
recurrence volume (RecVoli). MRI scans were registered to 
the RT planning CT and dose volume histograms were 
calculated for each RecVol. POF at the time of progression 
(POFp) and initial indication (POFi) were characterized by the 
percent volume encompassed within the 95% dose region as 
central (V95% ≥ 95%) or non-central (V95% < 95%). Here, POFp 
and POFi of each patient were categorized as central only, 
non-central only, or both central and non-central. 
Results: Of the collective patient cohort, POF appeared to 
become increasingly non-central and multifocal with time. 
Recurrence with a non-central component increased from 
14% to 27% (p = 0.07) and multifocal recurrence increased 
from 6% to 16% (p = 0.12) from the time of initial indication 
to progression, respectively. POF depended on the novel 
chemotherapy agent given. POFi were (94% central, 6% non-
central, 0% both) for erlotinib, (79%, 0%, 21%) for everolimus, 
and (77%, 18%, 5%) for vorinostat patient cohorts. Patients 
with unmethylated MGMT promoter had a higher percentage 
of multifocal recurrence (40%) compared to those with 
methylated MGMT promoter (0%) at the time of progression 
(p = 0.01). The overall median PFSi, PFSp, and OS were 4.5, 
8.6, and 17.4 months, respectively. Survival outcomes based 
on the novel chemotherapy agent given were not significantly 
different. 
Conclusions: POF for this ND-GBM cohort treated with novel 
chemotherapy agents were predominantly central, but were 
influenced by the time point of analysis. POF of the overall 
cohort were increasingly non-central at progression as 
compared with initial progression, suggesting that recurrence 
originates from the central region. POF differed between 
novel agents despite similar survival outcomes. Robust and 
properly-timed dosimetric POF analysis may be helpful to 
evaluate biologic aspects of novel therapeutic agents.  
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Purpose/Objective: To compare two schedules of 
hypofractionated radiochemotherapy in naive unresectable 
GBM in terms of toxicity, response and survival: the first one 
was followed by low dose radiation therapy (Hypo-RT-
CT+LDRT), in the second schedule no low dose radiation 
therapy was administered (Hypo-RT-CT). 
Materials and Methods: Patients (KPS > 70, age >18 years) 
underwent biopsy or with gross residual tumor after surgery 
were enrolled in these two studies. In the first study (Hypo-
RT-CT), patients received hypofractionated radiotherapy (35 
Gy in ten fractions) combined with Temozolomide (75 mg/mq 
from the start to the end of RT); in the second study (Hypo-
RT-CT+LDRT) patients received hypofractionated 
radiotherapy (30Gy in ten fractions) with concomitant 
Temozolomide. In both studies adjuvant Temozolomide 
(Stupp like) was administered but it was combined with low 
dose radiation therapy (40 cGy twice on day for 5 days) only 
in Hypo-RT-CT+LDRT study. In all cases clinical target volume 
(CTV) was ring enhancement with residual tumor plus 3 cm. 
Acute and late toxicities were evaluated according to 
Common Terminology Criteria for Adverse Events version 4.0. 
MRI was used in order to evaluate the response to the 
treatment, according to RECIST Guidelines. Moreover overall 
survival (OS) and progression-free survival (PFS) were 
calculated by the Kaplan-Mayer method. 
Results: Forty-two patients (M/F: 25/17) were enrolled from 
June 2010 to May 2014. Twenty-two out of 42 patients were 
enrolled in Hypo-RT-CT while 20 pts in Hypo-RT-CT+LDRT 
study. Most of them (57%) was submitted only to a biopsy 
(Table 1). Two out of 22 patients (9%) of Hypo-RT-CT study 
presented acute toxicities G2 (seizure and headache); in 
Hypo-RT-CT+LDRT we recorded G2 acute toxicities in 4 
patients (10%): 2 thrombocytopenia and 2 leucopenia; G3 
acute toxicity was observed only in one patient. After 
hypofractionated radiochemotherapy, partial response (PR) 
and stable disease (SD) were of 22% and 40% respectively in 
Hypo-RT-CT study, 9% and 14% in Hypo-RT-CT+LDRT. Median 
follow-up was of 24 months (range 6 - 53). Median OS and 1-
yrs survival were of 15 months and 75% respectively for Hypo-
